SCYNEXIS, Inc. Debt Conversion, Converted Instrument, Amount
SCYNEXIS, Inc. (SCYX) reported Debt Conversion, Converted Instrument, Amount of $6.00 million for the 1-month period ending 2021-01-31, per its 10-K filed 2022-03-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2022-03-29
- SCYNEXIS, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $4.00M.
| Period end | Debt Conversion, Converted Instrument, Amount 1 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|
| 2021-01-31 | $6.00M 10-K · filed 2022-03-29 | |
| 2020-12-31 | $2.00M 10-K · filed 2022-03-29 | $4.00M 10-K · filed 2022-03-29 |
| 2020-06-30 | $2.00M 10-K · filed 2022-03-29 | |
| 2014-12-31 | $0.00 8-K · filed 2015-10-30 | |
| 2013-12-31 | $14.02M 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |